https://www.selleckchem.com/pr....oducts/as2863619.htm
Background Brentuximab vedotin was approved for adult patients with CD30-expressing cutaneous T-cell lymphoma treated with prior systemic therapy based on improved response rates and progression-free survival with brentuximab vedotin (1.8 mg/kg once every 3 weeks; ≤16 cycles) versus physician's choice (methotrexate/bexarotene; ≤48 weeks) in the phase III ALCANZA study. Quality of life (QoL) in ALCANZA patients was also examined. Methods QoL measures in ALCANZA were based on the Skindex-29, Functional Assessment of Cancer Therapy-Gener
Like
Comment
Share
